Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 44

1.

Mitochondrial fission and stemness in prostate cancer.

Civenni G, Carbone GM, Catapano CV.

Aging (Albany NY). 2019 Sep 29. doi: 10.18632/aging.102339. [Epub ahead of print] No abstract available.

2.

Mitochondrial fission promotes self-renewal and tumorigenic potential in prostate cancer.

Civenni G, Carbone GM, Catapano CV.

Mol Cell Oncol. 2019 Jul 26;6(5):e1644598. doi: 10.1080/23723556.2019.1644598. eCollection 2019.

PMID:
31528704
3.

Efficacy of Novel Bromodomain and Extraterminal Inhibitors in Combination with Chemotherapy for Castration-Resistant Prostate Cancer.

Vázquez R, Civenni G, Kokanovic A, Shinde D, Cantergiani J, Marchetti M, Zoppi G, Ruggeri B, Liu PCC, Carbone GM, Catapano CV.

Eur Urol Oncol. 2019 Aug 8. pii: S2588-9311(19)30116-6. doi: 10.1016/j.euo.2019.07.013. [Epub ahead of print]

4.

Transcriptional Reprogramming and Inhibition of Tumor-propagating Stem-like Cells by EC-8042 in ERG-positive Prostate Cancer.

Shinde D, Albino D, Zoma M, Mutti A, Mapelli SN, Civenni G, Kokanovic A, Merulla J, Perez-Escuredo J, Costales P, Morìs F, Catapano CV, Carbone GM.

Eur Urol Oncol. 2019 Jul;2(4):415-424. doi: 10.1016/j.euo.2018.08.024. Epub 2018 Sep 24.

PMID:
31277777
5.

Transcriptional Reprogramming and Novel Therapeutic Approaches for Targeting Prostate Cancer Stem Cells.

Civenni G, Albino D, Shinde D, Vázquez R, Merulla J, Kokanovic A, Mapelli SN, Carbone GM, Catapano CV.

Front Oncol. 2019 May 9;9:385. doi: 10.3389/fonc.2019.00385. eCollection 2019. Review.

6.

Epigenetic Control of Mitochondrial Fission Enables Self-Renewal of Stem-like Tumor Cells in Human Prostate Cancer.

Civenni G, Bosotti R, Timpanaro A, Vàzquez R, Merulla J, Pandit S, Rossi S, Albino D, Allegrini S, Mitra A, Mapelli SN, Vierling L, Giurdanella M, Marchetti M, Paganoni A, Rinaldi A, Losa M, Mira-Catò E, D'Antuono R, Morone D, Rezai K, D'Ambrosio G, Ouafik L, Mackenzie S, Riveiro ME, Cvitkovic E, Carbone GM, Catapano CV.

Cell Metab. 2019 Aug 6;30(2):303-318.e6. doi: 10.1016/j.cmet.2019.05.004. Epub 2019 May 23.

PMID:
31130467
7.

Publisher Correction: Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer.

Chen J, Guccini I, Di Mitri D, Brina D, Revandkar A, Sarti M, Pasquini E, Alajati A, Pinton S, Losa M, Civenni G, Catapano CV, Sgrignani J, Cavalli A, D'Antuono R, Asara JM, Morandi A, Chiarugi P, Crotti S, Agostini M, Montopoli M, Masgras I, Rasola A, Garcia-Escudero R, Delaleu N, Rinaldi A, Bertoni F, de Bono J, Carracedo A, Alimonti A.

Nat Genet. 2018 Sep;50(9):1343. doi: 10.1038/s41588-018-0181-1.

PMID:
30089860
8.

Overview of Genetically Engineered Mouse Models of Prostate Cancer and Their Applications in Drug Discovery.

Civenni G, Carbone GM, Catapano CV.

Curr Protoc Pharmacol. 2018 Jun;81(1):e39. doi: 10.1002/cpph.39. Epub 2018 Jun 7. Review.

PMID:
29927081
9.

Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer.

Chen J, Guccini I, Di Mitri D, Brina D, Revandkar A, Sarti M, Pasquini E, Alajati A, Pinton S, Losa M, Civenni G, Catapano CV, Sgrignani J, Cavalli A, D'Antuono R, Asara JM, Morandi A, Chiarugi P, Crotti S, Agostini M, Montopoli M, Masgras I, Rasola A, Garcia-Escudero R, Delaleu N, Rinaldi A, Bertoni F, Bono J, Carracedo A, Alimonti A.

Nat Genet. 2018 Feb;50(2):219-228. doi: 10.1038/s41588-017-0026-3. Epub 2018 Jan 15. Erratum in: Nat Genet. 2018 Sep;50(9):1343.

10.

Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors.

Janouskova H, El Tekle G, Bellini E, Udeshi ND, Rinaldi A, Ulbricht A, Bernasocchi T, Civenni G, Losa M, Svinkina T, Bielski CM, Kryukov GV, Cascione L, Napoli S, Enchev RI, Mutch DG, Carney ME, Berchuck A, Winterhoff BJN, Broaddus RR, Schraml P, Moch H, Bertoni F, Catapano CV, Peter M, Carr SA, Garraway LA, Wild PJ, Theurillat JP.

Nat Med. 2017 Sep;23(9):1046-1054. doi: 10.1038/nm.4372. Epub 2017 Aug 14.

11.

Mitochondrial dysfunction induced by a SH2 domain-targeting STAT3 inhibitor leads to metabolic synthetic lethality in cancer cells.

Genini D, Brambilla L, Laurini E, Merulla J, Civenni G, Pandit S, D'Antuono R, Perez L, Levy DE, Pricl S, Carbone GM, Catapano CV.

Proc Natl Acad Sci U S A. 2017 Jun 20;114(25):E4924-E4933. doi: 10.1073/pnas.1615730114. Epub 2017 Jun 5.

12.

A promoter-proximal transcript targeted by genetic polymorphism controls E-cadherin silencing in human cancers.

Pisignano G, Napoli S, Magistri M, Mapelli SN, Pastori C, Di Marco S, Civenni G, Albino D, Enriquez C, Allegrini S, Mitra A, D'Ambrosio G, Mello-Grand M, Chiorino G, Garcia-Escudero R, Varani G, Carbone GM, Catapano CV.

Nat Commun. 2017 May 30;8:15622. doi: 10.1038/ncomms15622.

13.

Targeting Promoter-Associated Noncoding RNA In Vivo.

Civenni G.

Methods Mol Biol. 2017;1543:259-270. doi: 10.1007/978-1-4939-6716-2_15.

PMID:
28349433
14.

MicroRNA-424 impairs ubiquitination to activate STAT3 and promote prostate tumor progression.

Dallavalle C, Albino D, Civenni G, Merulla J, Ostano P, Mello-Grand M, Rossi S, Losa M, D'Ambrosio G, Sessa F, Thalmann GN, Garcia-Escudero R, Zitella A, Chiorino G, Catapano CV, Carbone GM.

J Clin Invest. 2016 Dec 1;126(12):4585-4602. doi: 10.1172/JCI86505. Epub 2016 Nov 7.

15.

A Small-Molecule Inhibitor of Lin28.

Roos M, Pradère U, Ngondo RP, Behera A, Allegrini S, Civenni G, Zagalak JA, Marchand JR, Menzi M, Towbin H, Scheuermann J, Neri D, Caflisch A, Catapano CV, Ciaudo C, Hall J.

ACS Chem Biol. 2016 Oct 21;11(10):2773-2781. Epub 2016 Aug 22.

PMID:
27548809
16.

The ETS factor ESE3/EHF represses IL-6 preventing STAT3 activation and expansion of the prostate cancer stem-like compartment.

Albino D, Civenni G, Rossi S, Mitra A, Catapano CV, Carbone GM.

Oncotarget. 2016 Nov 22;7(47):76756-76768. doi: 10.18632/oncotarget.12525.

17.

Activation of the Lin28/let-7 Axis by Loss of ESE3/EHF Promotes a Tumorigenic and Stem-like Phenotype in Prostate Cancer.

Albino D, Civenni G, Dallavalle C, Roos M, Jahns H, Curti L, Rossi S, Pinton S, D'Ambrosio G, Sessa F, Hall J, Catapano CV, Carbone GM.

Cancer Res. 2016 Jun 15;76(12):3629-43. doi: 10.1158/0008-5472.CAN-15-2665. Epub 2016 May 2.

18.

EC-70124, a Novel Glycosylated Indolocarbazole Multikinase Inhibitor, Reverts Tumorigenic and Stem Cell Properties in Prostate Cancer by Inhibiting STAT3 and NF-κB.

Civenni G, Longoni N, Costales P, Dallavalle C, García Inclán C, Albino D, Nuñez LE, Morís F, Carbone GM, Catapano CV.

Mol Cancer Ther. 2016 May;15(5):806-18. doi: 10.1158/1535-7163.MCT-15-0791. Epub 2016 Jan 29.

19.

Short loop-targeting oligoribonucleotides antagonize Lin28 and enable pre-let-7 processing and suppression of cell growth in let-7-deficient cancer cells.

Roos M, Rebhan MA, Lucic M, Pavlicek D, Pradere U, Towbin H, Civenni G, Catapano CV, Hall J.

Nucleic Acids Res. 2015 Jan;43(2):e9. doi: 10.1093/nar/gku1090. Epub 2014 Nov 6.

20.

Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity.

Toso A, Revandkar A, Di Mitri D, Guccini I, Proietti M, Sarti M, Pinton S, Zhang J, Kalathur M, Civenni G, Jarrossay D, Montani E, Marini C, Garcia-Escudero R, Scanziani E, Grassi F, Pandolfi PP, Catapano CV, Alimonti A.

Cell Rep. 2014 Oct 9;9(1):75-89. doi: 10.1016/j.celrep.2014.08.044. Epub 2014 Sep 25.

Supplemental Content

Loading ...
Support Center